This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: Continuous monitoring of SpO2 throughout the 6-min walk test (6MWT) unveiled that some patients with respiratory diseases may present values across the test lower than SpO2 measured at the end of the test. Nevertheless, it remains unclear whether this approach improves the yield of walk-induced desaturation detection in predicting mortality and hospitalizations in patients with COPD.
METHODS: Four hundred twenty-one subjects (51% males) with mild−very severe COPD underwent a 6MWT with continuous measurement of SpO2. Exercise desaturation was defined as a fall in SpO2 ≥ 4%. All-cause mortality was assessed up to 6 y of follow-up and the rate of hospitalizations in the year succeeding the 6MWT.
RESULTS: One hundred forty-nine subjects (35.4%) died during a mean (interquartile) follow-up of 55.5 (30.2−64.1) months. Desaturation was observed in 299/421 (71.0%). SpO2 along the test was < end SpO2 (88 [82−92]% vs 90 [84−93]%, P < .001). Desaturation detected only during (but not at the end of) the test was found in 81/421 (19.2%) participants. Multivariate Cox regression model adjusted for sex, body composition, FEV1, residual volume/total lung capacity ratio, walk distance, O2 supplementation during the test, and comorbidities retained the presence of desaturation either at the end (1.85 [95% CI 1.02−3.36]) or only along the test (2.08 [95% CI 1.09−4.01]) as significant predictors of mortality. The rate of hospitalizations was higher in those presenting with any kind of desaturation compared to those without exercise desaturation. Logistic regression analysis revealed that walking interruption and diffusing capacity of the lung for carbon monoxide predicted desaturation observed only during the test.
CONCLUSIONS: O2 desaturation missed by end-exercise SpO2 but exposed by measurements during the test was independently associated with all-cause mortality and hospitalizations in subjects with COPD.
Footnotes
- Correspondence: Danilo C Berton MD PhD, Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul, Unidade de Fisiologia Pulmonar, Serviço de Pneumologia, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Sala 2050, CEP 90035–003, Porto Alegre, RS, Brasil. E-mail: dberton{at}hcpa.edu.br
The authors have disclosed no conflicts of interest.
Dr Berton presented a version of this manuscript at the European Respiratory Society International Congress 2021, held virtually September 5−8, 2021.
The study was supported by Incentive Fund of Research of Hospital de Clinicas de Porto Alegre (grant number: 20200207); Dr Berton receives a research fellowship from the Brazilian National Council for Scientific and Technological Development (grant number: 304061/2019-0).
- Copyright © 2023 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
